Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

On Wednesday, Bio-Rad Labs ABIO got an upgrade to its Relative Strength (RS) Rating, from 69 to 72. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The Day How ...

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf Partners Global Fund”. A copy of the letter can be downloaded here. The Fund ...

Hello, everyone, and welcome to today's Bio-Rad Third Quarter 2024 Results Conference Call and Webcast. At this time to get started, all participants are in a listen-only mode. Later, you will have ...

Aug 1 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.

Oct 30 (Reuters) - Diagnostics firm Bio-Rad Laboratories (BIO.N), opens new tab posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical ...

View Bio-Rad Laboratories, Inc. Class B BIO.B stock quote prices, financial information, real-time forecasts, and company news from CNN.